Optimizing Cryovial Filling And Cryopreservation For Reliable Cell Functionality

Cell therapy manufacturing at scale demands cryopreservation workflows that protect not just cell survival, but the functional properties that determine therapeutic success. Standard approaches often fall short, introducing variability through manual processes and failing to preserve the expansion kinetics, cytotoxic activity, and colony-forming capacity essential for reliable outcomes.

Discover how integrated automation addresses these critical gaps by minimizing the time between cryoprotectant addition and freezing while enabling controlled-rate, directional ice growth. This combination reduces mechanical stress on cells and supports lower cryoprotectant concentrations without compromising performance. Recent research demonstrates functional recovery rates of 20-50% in colony-forming units using just 2.5% DMSO, significantly less than conventional protocols, while maintaining 80% post-thaw viability even at 1% DMSO. Learn how this workflow approach delivers the consistency and scalability needed to advance both early-stage research and clinical-scale production.

Access the article below for additional insights into what makes directional freezing technology fundamentally different from radial methods and why functional assessment matters more than viability alone.